# Suzanne Blaug

> Suzanne Blaug is a startup investor at Amgen Ventures. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures)
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/suzanne-blaug-106a1b11a

Suzanne Blaug is a startup investor at Amgen Ventures. Suzanne Blaug joined Amgen in Thousand Oaks, California, as Senior Vice President of Global Marketing and Commercial Development in April 2012. In this role, Blaug is responsible for providing commercial leadership and influencing key decisions for Amgen products at all stages of the product lifecycle and for maximizing the value of each individualfranchise.Prior to joining Amgen, Blaug was the head of Janssen Alzheimer Immunotherapy Research & Development, LLC, a Johnson & Johnson company in South San Francisco, California.Prior to joining Janssen Al, she served as vice president, Strategic Marketing of Janssen EMEA, where she helped drive growth of a number of brands, as well as the successful launches of new franchises.She joined Johnson & Johnson in 2004 as area managing director.Blaug received a BS from the University of North Carolina in Chapel Hill and an MBA in Marketing & Finance from JL Kellogg Graduate School of Management, Northwestern University in Evanston, Illinois. Blaug has worked in the pharmaceutical and biotechnology industry for more than 20 years.

## About Amgen Ventures

VC Fund · San Francisco, United States

Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.

2 contacts available at Amgen Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Suzanne Blaug | SVP, Global Marketing and Commercial Development | https://shizune.co/investors/profile/suzanne-blaug |
| Philip Tagari | VP Research | https://shizune.co/investors/profile/philip-tagari |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co